OTC Markets Stock News
Biotech
-
11.5KWhy Novan Stock (NASDAQ:NOVN) Is Gearing Up For A Big Move
Novan Stock (NASDAQ:NOVN) is a name that we have covered on and off here at Insider Financial. We first covered it back...
-
8.8K3Is Aytu Bioscience (NASDAQ:AYTU) About To Merge With Cerecor (NASDAQ:CERC)?
The buzz all over the Internet is that there’s going to be a tie-up between Aytu Bioscience (NASDAQ:AYTU) and Cerecor (NASDAQ:CERC). The chatter...
-
5.8KWhy InspireMD Stock (NYSEMKTS:NSPR) Is Heading Higher
The key to successful investing is finding momentum BEFORE it happens. Just last week, we had our subscribers in Genius Brands International...
-
11.6KIs Biocept Stock (NASDAQ:BIOC) About To Make A Huge Move?
Biocept Stock (NASDAQ:BIOC) is a name that we have covered on and off since 2017. Biocept Stock has been a horrible investment...
-
7.2KWill Dynavax Stock (NASDAQ:DVAX) Keep Climbing?
Dynavax Stock (NASDAQ:DVAX) is the talk of the small cap biotech world after climbing more than 50% over the past two trading...
-
3.6KSPO Global Inc (OTCMKTS:SPOM) Up 300% As Medical Services Footprint Grows
The only reason to trade penny stocks is for the explosive moves they can make. If a penny stock doesn’t have triple-digit...
-
13.0KWill Abbott Labs (NYSE:ABT) Buy Co-Diagnostics Inc (NASDAQ:CODX)?
We said in March that Co-Diagnostics Inc (NASDAQ:CODX) was destined for new highs when the stock was trading around $10 a share. With...
-
3.1KProgressive Care Inc (RXMD Stock) e-Commerce Opportunity Fueled By COVID-19
Progressive Care Inc (RXMD Stock) is adapting nicely to a challenging economic landscape triggered by the Covid-19 pandemic. The company’s e-commerce operations...
-
7.0KIs Alpha Pro Tech Ltd (NYSEAMERICAN:APT) About To Make Another Big Move?
The only reason to trade coronavirus stocks is for the explosive moves they can make. If a penny stock doesn’t have triple-digit...
-
10.6K1Gilead (NASDAQ: GILD) Shares Jump On Trial Results and Fauci Despite 9.3% Mortality Rate After 14 Days
Today Gilead Sciences (NASDAQ: GILD) was making a splash about their phase 3 trial results but all this trial essentially did was...
